Publications by authors named "J S Sohal"
Pharmacogenomic (PGx) testing can help personalise psychiatric prescribing and improve on the currently adopted trial-and-error prescribing approach. However, widespread implementation is yet to occur. Understanding factors influencing implementation is pertinent to the psychiatric PGx field.
View Article and Find Full Text PDFArticle Synopsis
- - The study investigates the prevalence of mono-resistance to rifampicin and isoniazid in tuberculosis (TB) patients in Western Uttar Pradesh, finding that 19.51% were multi-drug resistant while 8.54% and 6.10% were mono-resistant to rifampicin and isoniazid, respectively.
- - Out of 153 sputum samples processed, 54.24% tested positive for Mycobacterium tuberculosis, with the majority being identified through specific culture and testing methods.
- - Findings indicate a higher occurrence of mono-resistance in male patients over 45, those living in rural areas, experiencing weight loss, or with previous TB treatment; the study calls for better monitoring
Article Synopsis
- Inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, is rising in incidence, especially in countries like India, where it has become the second highest in the world.* -
- The disease is linked to an inappropriate immune response involving various helper T cell subsets and their cytokines, which contribute to gut inflammation and severity.* -
- The review discusses how different T cell types, including CD8, NKT, and γδT cells, affect IBD outcomes and also explores potential therapeutic options for managing the disease.*
Article Synopsis
- * 75% of emerging diseases in the last decade come from animals, posing serious health and economic risks, largely due to new pathogens causing widespread outbreaks.
- * Effective control of zoonotic diseases requires collaboration across health sectors for improved diagnosis, monitoring, vaccination, and public awareness to mitigate impacts on human health.
Background: Prescribing drugs for psychosis (antipsychotics) is challenging due to high rates of poor treatment outcomes, which are in part explained by an individual's genetics. Pharmacogenomic (PGx) testing can help clinicians tailor the choice or dose of psychosis drugs to an individual's genetics, particularly psychosis drugs with known variable response due to CYP2D6 gene variants ('CYP2D6-PGx antipsychotics').
Aims: This study aims to investigate differences between demographic groups prescribed 'CYP2D6-PGx antipsychotics' and estimate the proportion of patients eligible for PGx testing based on current pharmacogenomics guidance.